Introduction: Gastric cancer (GC) is the fifth most common type of cancer worldwide, according to the International Agency for Research on Cancer. It is characterized by a high incidence, poor prognosis, and resistance to conventional treatments, making it a global health problem. In the northern region of Brazil, GC ranks as the second most common cancer among men and the fifth among women, according to the National Cancer Institute. In this context, the use of natural products has emerged in the scientific field as a form of alternative therapy, due to their significant medicinal properties, especially anti-inflammatory, anti-proliferative, and antineoplastic activities, making the investigation of the antineoplastic potential of widely used Amazonian species a promising approach. Objectives: To evaluate the in vitro antineoplastic effect of an essential oil derived from the Piperaceae family on two gastric tumor cell lines: AGP-01 and AGP-01 PIWI Knockout(-/-). Methods: The AGP-01, AGP-01 PIWI-/-, and non-neoplastic HEK-293 cell lines were cultured in DMEM supplemented with 10% fetal bovine serum and 1% antibiotics, and maintained in an incubator at 37°C with a 5% CO? atmosphere. To evaluate the substance’s effect on cell viability, the MTT assay, an in vitro cytotoxicity technique used in tumor cells, was performed. Cells were plated in 96-well plates at a concentration of 3 x 10³ cells/well. The essential oil was dissolved in dimethyl sulfoxide (DMSO) to obtain an initial concentration of 15mg/mL, and treatments were performed using a concentration gradient ranging from 100 to 1.56µg/mL, maintained for 72 hours in a CO? incubator. After treatment, the supernatant was aspirated, followed by the addition of 100 µL of MTT solution at 0,5mg/mL, and incubation for 3 hours. Finally, the supernatant was aspirated, and the formazan crystals were resuspended in 100µL of DMSO, allowing the analysis in a plate spectrophotometer at a wavelength of 570nm. Results: The half-maximal inhibitory concentration (IC??) values after 72 hours of treatment were 13.82µg/mL for the AGP-01 line and 7.55µg/mL for the AGP-01 PIWI-/- line. The non-neoplastic HEK-293 line showed an IC?? higher than 100µg/mL, indicating only a slight reduction in cell metabolism at the highest treatment concentrations, and demonstrating low cytotoxic activity when compared to the tumor cell lines. Conclusion: The results demonstrate that the oil exhibits significant cytotoxic activity against the analyzed cell lines, based on the IC?? values mentioned above. The increased sensitivity observed in the AGP-01 PIWI-/- line suggests that the absence of PIWIL1 gene expression may render the cells more susceptible to the compound’s effect, indicating a potential therapeutic strategy in such cases. These findings reinforce the therapeutic potential of the compound and highlight the importance of further investigation into natural products from the Brazilian Amazon region.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
